Loading...
XSTO
ENZY
Market cap41mUSD
Oct 09, Last price  
1.71SEK
1D
-2.29%
1Q
-31.05%
Jan 2017
-34.45%
IPO
-67.72%
Name

Enzymatica AB (publ)

Chart & performance

D1W1MN
XSTO:ENZY chart
P/E
—
P/S
7.70
EPS
—
Div yield, %
—
Shrs. gr., 5y
11.18%
Rev. gr., 5y
-13.49%
Revenues
54m
+18.27%
00582,000895,00010,489,00019,063,00027,912,00036,482,00059,446,00052,560,00061,306,000111,245,00057,243,00048,948,00050,904,00045,575,00053,903,000
Net income
-52m
L-2.42%
-190,096-190,096-4,987,000-7,568,000-16,208,000-32,393,000-40,830,000-45,006,000-31,445,000-42,579,000-40,979,000-13,221,000-45,393,000-68,657,000-49,728,000-53,179,000-51,890,000
CFO
-41m
L-32.29%
-101,988-4,856,000-7,253,000-18,429,000-40,666,000-37,648,000-38,434,000-22,545,000-28,792,000-37,576,000-10,652,000-35,869,000-64,566,000-40,287,000-60,507,000-40,972,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.

Related entities

Subsidiaries
Enzymatica Care AB

Key people

Therese Filmersson
Chief Financial Officer · since 2018
Mats Clarsund
Executive Vice President Research and Development · since 2012
Johan Lindvall
Chief Operating Officer, Executive Vice President · since 2017
Anna Isaksson
Vice President Quality and Regulatory Management · since 2016
Jorgen Rexo
Executive Vice President Legal · since 2016
Claus Egstrand
Chief Commercial Officer · since 2017
Ulf Blom
Executive Vice President Marketing and Operations · since 2013
Mats K. Andersson
Director · since 2016
Louise Nicolin
Director · since 2016
Gudmundur Palmason
Director · since 2016
URL
https://www.enzymatica.se/
IPO date
Jun 14, 2011
Employees
21
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Ideon Science Park
Lund, M 223 70
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT